BOXED O
WARNING O
: O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
Infusion O
Reactions O
Rituxan O
administration O
can O
result O
in O
serious O
, O
including O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
within O
24 O
hours O
of O
Rituxan O
infusion O
have O
occurred O
. O

Approximately O
80 O
% O
of O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
association O
with O
the O
first O
infusion O
. O

Monitor O
patients O
closely O
. O

Discontinue O
Rituxan O
infusion O
for O
severe O
reactions O
and O
provide O
medical O
treatment O
for O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Severe O
Mucocutaneous O
Reactions O
Severe O
, O
including O
fatal B-NonOSE_AE
, O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
Rituxan O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Hepatitis O
B O
Virus O
( O
HBV O
) O
Reactivation O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
Rituxan O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis B-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
treatment O
initiation O
, O
and O
monitor O
patients O
during O
and O
after O
treatment O
with O
Rituxan O
. O

Discontinue O
Rituxan O
and O
concomitant O
medications O
in O
the O
event O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
including O
fatal B-NonOSE_AE
PML B-OSE_Labeled_AE
, O
can O
occur O
in O
patients O
receiving O
Rituxan O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Fatal O
infusion O
reactions O
within O
24 O
hours O
of O
Rituxan O
infusion O
; O
approximately O
80 O
% O
of O
fatal O
reactions O
occurred O
with O
first O
infusion O
. O

Monitor O
patients O
and O
discontinue O
Rituxan O
infusion O
for O
severe O
reactions O
( O
5.1 O
) O
. O

* O
Severe O
mucocutaneous O
reactions O
, O
some O
with O
fatal O
outcomes O
( O
5.2 O
) O
. O

* O
Hepatitis O
B O
virus O
( O
HBV O
) O
reactivation O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis O
, O
hepatic O
failure O
, O
and O
death O
( O
5.3 O
) O
. O

* O
Progressive O
multifocal O
leukoencephalopathy O
( O
PML O
) O
resulting O
in O
death O
( O
5.4 O
) O
. O

